Pyrazines

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. 
  • A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. 
  • Activation by odorants of a multistate cation channel from olfactory cilia. 
  • Activation of NAD(P)H oxidase by lipid hydroperoxides: mechanism of oxidant-mediated smooth muscle cytotoxicity. 
  • Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. 
  • Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. 
  • Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. 
  • Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. 
  • Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. 
  • Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. 
  • Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma. 
  • Coordinated cerebellar climbing fiber activity signals learned sensorimotor predictions. 
  • Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. 
  • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. 
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effect of amiloride and some of its analogues of cation transport in isolated frog skin and thin lipid membranes. 
  • Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. 
  • Effects of chemical group specific reagents on sodium entry and the amiloride binding site in frog skin: evidence for separate sites. 
  • Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. 
  • Function of nuclear factor kappaB in pancreatic cancer metastasis. 
  • Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. 
  • HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. 
  • Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. 
  • Multiple myeloma, version 1.2013. 
  • Neihumicin, a new cytotoxic antibiotic from Micromonospora neihuensis. II. Structural determination and total synthesis. 
  • New combination treatments in the management of diabetes: focus on sitagliptin-metformin. 
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. 
  • PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. 
  • PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. 
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. 
  • Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. 
  • Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Safety and efficacy of weekly oral oltipraz in chronic smokers. 
  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. 
  • Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. 
  • Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 
  • Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. 
  • Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-beta inhibitors. 
  • Tetramethylpyrazine (TMP), an Active Ingredient of Chinese Herb Medicine Chuanxiong, Attenuates the Degeneration of Trabecular Meshwork through SDF-1/CXCR4 Axis. 
  • The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. 
  • The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes. 
  • What should work, may not.